Carriage of S. aureus and interaction with the nasal microbiome

Completed

• Conditions: S. aureus carriage; 10004018; 10040785

• Registration Number: NL-OMON48845
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 70

Inclusion Criteria

Volunteers must be over 18 years old

Exclusion Criteria

- Employee of the Erasmus MC
- Intermittent carrier of Staphylococcus aureus
- Use of drugs influencing microbiome in 3 months prior to the study period
i.e. antibiotics, antiparasitics or antifungals
- Regular use of commercial probiotics in 3 months prior to the study period
- Known allergy to components of the intervention treatment (see Ch 5.1)
- Pregnant and breastfeeding women, due to limited scientific evidence on
adverse effects of mupirocin treatment during pregnancy and breastfeeding.
- Known chronic diseases affecting the immune system (such as diabetes
mellitus, renal insufficiency, COPD, heart diseases, immunocompromised status
(HIV, AIDS), skin diseases such as severe eczema or use of immunosuppressant
drugs

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Microbiome composition of the nose, to be analysed in relation to S. aureus<br /><br>carrier status and decolonization.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>NA</p><br>